首页> 外文期刊>Blood purification >Isonatric Dialysis Biofeedback in Hemodiafiltration with Online Regeneration of Ultrafiltrate in Hypertensive Hemodialysis Patients: A Randomized Controlled Study
【24h】

Isonatric Dialysis Biofeedback in Hemodiafiltration with Online Regeneration of Ultrafiltrate in Hypertensive Hemodialysis Patients: A Randomized Controlled Study

机译:高血压血液透析患者血液透析滤过中的等渗透析生物反馈和超滤液的在线再生:一项随机对照研究

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

Dialysis biofeedback in hemodiafiltration with online regeneration of ultrafiltrate (HFR) could help to improve arterial hypertension. We evaluated the impact of isonatric HFR (HFR-iso) on hypertension control compared to conventional HFR. Forty-seven hemodialysis patients were included and randomized (ratio 2/1) HFR-iso versus HFR during 24 dialysis sessions. In the HFR-iso group (32 patients, 768 dialysis sessions), the predialytic systolic blood pressure (BP) decreased from S1 to S24 of 9 +/- 20 mm Hg and increased of 5 +/- 24 mm Hg in the HFR group (15 patients, 360 dialysis sessions), variation that differed between the 2 groups (Delta S1-S24, p = 0.035; interaction group*time, p = 0.012). The diastolic BP (HFR-iso -3 +/- 14 mm Hg vs. HFR 5 +/- 13 mm Hg; p = 0.088), the DDD of antihypertensive treatment and the dry weight did not vary significantly during the study. Number of sessions complicated by symptomatic hypotension was similar in the 2 groups. HFR-iso improved BP control without increasing dialysis hypotension episodes. Short Summary: In this multicenter, open-label, controlled, randomized study, we evaluated the impact of dialysis biofeedback in HFR on arterial hypertension compared to conventional HFR. We observed that HFR-iso improved arterial BP control without increasing dialysis hypotension episodes. (C) 2015 S. Karger AG, Basel
机译:血液透析滤过中的透析生物反馈与超滤液(HFR)的在线再生可以帮助改善动脉高血压。与常规HFR相比,我们评估了等渗HFR(HFR-iso)对高血压控制的影响。纳入了47例血液透析患者,并在24个透析期间将HFR-iso与HFR进行了随机(比例2/1)对比。在HFR-iso组(32例患者,进行768次透析),HFR组的透析前收缩压(BP)从S1降至S24为9 +/- 20 mm Hg,增加5 +/- 24 mm Hg (15位患者,进行360次透析),两组之间的差异有所不同(Delta S1-S24,p = 0.035;交互作用组*时间,p = 0.012)。在研究期间,舒张压BP(HFR-iso -3 +/- 14 mm Hg与HFR 5 +/- 13 mm Hg; p = 0.088),降压治疗的DDD和干重无明显变化。两组并发症状性低血压的次数相似。 HFR-iso可改善BP控制,而不会增加透析性低血压发作。简短摘要:在这项多中心,开放标签,对照,随机研究中,我们评估了与传统HFR相比,HFR中透析生物反馈对动脉高血压的影响。我们观察到HFR-iso在不增加透析低血压发作的情况下改善了动脉血压控制。 (C)2015 S.Karger AG,巴塞尔

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号